In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors.
Michael J NorrisCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA.
Lauren A HendersonDepartment of Microbiology and Immunology, Louisiana State University Health Shreveport, Shreveport, Shreveport, LA.ORCID 0000-0002-2379-3643 Mohammed N A SiddiqueyDepartment of Microbiology and Immunology, Louisiana State University Health Shreveport, Shreveport, Shreveport, LA.ORCID 0000-0001-8803-3242 Jieyun YinCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA.
Kwangsun YooCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA.
Simon BrunelCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA.
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA.ORCID 0000-0002-1206-7451 Chris A BenedictCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA.
Jeremy P KamilDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA.ORCID 0000-0001-8422-7656 Funding
The role of TRAIL in immune control of cytomegalovirusR01AI101423 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2013 to 2023
$4.6MRoles of the UL148 glycoprotein in human cytomegalovirus infectionR01AI116851 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jeremy Phillip Kamil · 2016 to 2026
$3.5MCD4 T cell control of cytomegalovirusR01AI139749 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2019 to 2023
$3.2MMultidisciplinary Training in Cardiovascular PathophysiologyT32HL155022 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE, STOKES, KAREN Y · 2021 to 2025
$619kThe role of TRAIL in immune control of cytomegalovirusR56AI101423 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2012 to 2012
$435kNHLBI NIH HHS T32 HL155022NIAID NIH HHS R01 AI101423NIAID NIH HHS R01 AI116851NIAID NIH HHS R01 AI139749NIAID NIH HHS R56 AI101423
6 · The paper itselfAbstract
Human cytomegalovirus (HCMV) causes severe birth defects, lifelong health complications, and $4 billion in annual costs in the United States alone. A major challenge in vaccine design is the incomplete understanding of the diverse protein complexes the virus uses to infect cells. In
Identifiers
PMID39416215
PMCPMC11482907
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390